ABL Diagnostics (XPAR:ABLD) ROCE % : -9.06% (As of Jun. 2023)

View and export this data going back to 1989. Start your Free Trial

What is ABL Diagnostics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ABL Diagnostics's annualized ROCE % for the quarter that ended in Jun. 2023 was -9.06%.

ABL Diagnostics ROCE % Historical Data

The historical data trend for ABL Diagnostics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABL Diagnostics ROCE % Chart

ABL Diagnostics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

0.78

-0.96

-1.91

-4.14

8.06

ABL Diagnostics Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial															-3.75	-4.17	-9.14	20.10	-9.06

ABL Diagnostics ROCE % Calculation

ABL Diagnostics's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	0.503	/	( ( (2.713 - 0.094)	+	(15.408 - 5.55) )	/ 2 )
	=	0.503	/	( (2.619	+	9.858)	/ 2 )
	=	0.503	/	6.2385
	=	8.06 %

ABL Diagnostics's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-0.926	/	( ( (15.408 - 5.55)	+	(16.372 - 5.787) )	/ 2 )
	=	-0.926	/	( ( 9.858	+	10.585 )	/ 2 )
	=	-0.926	/	10.2215
	=	-9.06 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

ABL Diagnostics (XPAR:ABLD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ABL Diagnostics ROCE % Related Terms

Thank you for viewing the detailed overview of ABL Diagnostics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ABL Diagnostics (XPAR:ABLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » ABL Diagnostics (XPAR:ABLD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

72c, rue de, WOIPPY, Thionville, FRA, 57140

Website

https://www.abldiagnostics.com

ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.

ABL Diagnostics (XPAR:ABLD) Headlines

No Headlines